<i>In vivo</i> Therapeutic Synergism of Anti–Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic CarcinomasChristel Larbouret, D. Azria|Clinical Cancer Research|2007Cited by 84
Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancerCharline Ogier, Christel Larbouret, Martine Pugnière et al.|Cancer Letters|2018Cited by 57
Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenograftsChristel Larbouret, D. Azria|Annals of Oncology|2009Cited by 49
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical modelsGaëlle Thomas, Christel Larbouret|Oncotarget|2014Cited by 44
Inhibiting microtubule polymerization with EAPB02303, a prodrug activated by catechol-O-methyl transferase, enhances paclitaxel effect in pancreatic cancer modelsKévin Bigot, Christel Larbouret, Cindy Patinote et al.|Cell Death and Disease|2025Cited by 1